Introduction
============

Systems approaches to disease arise from a simple hypothesis---disease emerges from the functioning of one or more disease-perturbed networks (genetic and/or environmental perturbations) that alter the levels of proteins and other informational molecules controlled by these networks. The dynamically changing levels of disease-perturbed proteins (networks) across disease progression presumably explain the mechanisms of the disease. Systems approaches to biology or medicine have two cardinal features: (1) global analyses to generate comprehensive data sets in the disease-relevant organ or cells across the dynamically changing disease process (e.g. all mRNA, miRNA, or protein levels) and (2) the integration of different levels of biological information (DNA, mRNA, miRNA, protein, interactions, metabolites, networks, tissues, organs, and phenotypes) to generate hypotheses about the fundamental principles of the disease ([@b34]). In this study, we present a systems biology approach that effectively uses these two features, uses multiple inbred mouse strains, uses a deep understanding of prion biology and applies statistical data integration methods to deal with two striking challenges: (1) sorting out the signal-to-noise issues arising from the global disease-associated changes as both measurement noise and biological noise and (2) reducing enormous data dimensionality so that the processes can be identified and visualized for study. The keys to reducing this noise are to apply a deep understanding of biology to carry out subtractive data analyses that focus on particular biological issues---as well as to use integrative statistical methods. We applied the systems approach to experimentally tractable neurodegenerative diseases caused by prion infection of mice. Analysis of a large data set (∼20 million data points) revealed slightly more than 300 differentially expressed genes (DEGs) that may encode fundamental processes in prion disease.

Prions are unique among transmissible, disease-causing agents in that they replicate by conformational conversion of normal benign forms of prion protein (PrP^C^) to disease-specific PrP^Sc^ isoforms. Neuropathological features common to all prion diseases in mammals, which include bovine spongiform encephalopathy (BSE) in cows, Creutzfeldt--Jakob disease (CJD) in humans, and scrapie in sheep, can be conveniently subdivided into four processes: prion (PrP^Sc^) replication and accumulation ([@b70]), synaptic degeneration ([@b38]), microglia and astrocyte activation ([@b73]; [@b65]), and neuronal cell death ([@b49]). There exist distinct strains of infectious prions that have different properties (e.g. duration of incubation time, sites of infection in the brain, and so on) that presumably arise from distinct structural forms of misfolded prion proteins (e.g. distinct three-dimensional structures and/or chemical modifications).

Changes in gene expression induced by prion infection were followed at multiple time points in diverse mouse--prion combinations over the entire course of the incubation times with end points ranging from 56 to 392 days ([Figure 1](#f1){ref-type="fig"} and [Table I](#t1){ref-type="table"}: incubation time is defined as the time period from prion infection to an end point, where all mice in each combination showed end-stage clinical signs of prion disease (except for *Prnp*-null (0/0) mice)). Three factors responsible for this wide range in incubation times are represented in our mouse strain--prion strain combinations: (1) distinct prion strains can produce different incubation times in genetically identical hosts, (2) host genotype determines incubation times for a prion strain with the allelic forms of the PrP gene (*Prnp*) having the strongest effect, and (3) concentrations of PrP affect the incubation times. Infected animals exhibit no signs of illness over most of their incubation periods. The dynamically changing DEGs were mapped onto a series of known protein interaction maps and integrated with histopathological data on PrP^Sc^ accumulation and distribution in the brain at multiple time points during disease incubation. This integration was used to develop hypothetical molecular subnetworks presumably encoding various cellular processes that are perturbed by prion infection and these hypotheses were validated by statistical and biological assessments of the DEGs central to prion disease. The networks identify perturbations of cellular processes that appear essential for prion replication and also the interactions of such processes with subnetworks involved in pathological changes. With the exception of the prion replication and accumulation network, similar changing network processes are seen in other neurodegenerative disorders, including Alzheimer\'s disease ([@b8]; [@b85]).

It is important to stress that dynamic biological networks may change in two ways---the transcripts of the nodal points in the network may change in concentration or chemical structure; the architecture of the network may change in the nature of its connections or interactions. One of the grand challenges of systems biology is to develop methods that may easily measure the dynamically changing architecture of networks---and currently we are unfortunately forced to map or correlate the dynamical changes in transcripts, histopathology and clinical signs onto networks, the dynamics of which are revealed only by changes in the concentrations of mRNAs. Even with this coarse granularity of understanding, powerful insights into the nature of prion disease emerge from the correlation of histopathology, clinical signs and dynamical networks---explaining much of what we already know about this disease mechanistically in terms of biological network behavior as well as beginning to providing insights into new pathogenic mechanisms and potential strategies for therapeutic intervention.

Results
=======

Microarray analysis of gene expression
--------------------------------------

To facilitate the identification of differential gene expression relevant to essential processes in prion replication and disease, we selected the mouse strain--prion strain combinations shown in [Table I](#t1){ref-type="table"}. The combinations reflect three different factors that can dramatically impact the incubation time: prion strain, host genotype, and PrP concentration. Two prion strains, Rocky Mountain Lab (RML) mouse-adapted scrapie prions and 301V mouse-adapted BSE prions, produce dramatically different incubation times in a single inbred strain of mice. For example, C57BL/6J (B6) mice inoculated with RML (B6-RML) have short incubation times compared with B6 mice inoculated with 301V prions (B6-301V) (see [Table I](#t1){ref-type="table"}). Host genotype also affects incubation time ([@b92]). Indeed, alternative alleles of the PrP gene, *Prnp*, encode distinct proteins that dramatically alter incubation time. B6 and B6.I-*Prnp*^*b*^ (B6.I) mice are congenic for the interval on Chr 2 that contains *Prnp* ([@b17], [@b18]). B6 mice inoculated with RML prions (B6-RML) have short incubation times, whereas B6.I (*Prnp*^*b*^) mice inoculated with the same prion strain (B6.I-RML) have long RML incubation times owing to their different PrP sequences ([@b92]). The converse is true for 301V prions (B6-301V and B6.I-301V) with B6.I mice having shorter incubation times than B6 mice ([@b14]; [@b18]). Thus, it is important to stress that long incubation time is not an inherent property of either *Prnp* genotype or prion strain, but reflects interactions between the host and the agent.

PrP concentration also affects incubation time. The FVB/NCr (FVB) genetic background was used for testing effects of the level of PrP expression on gene expression in prion disease. Mice that are heterozygous for a null allele of *Prnp*, (FVB.129-*Prnp*^*tm1Zrch*^ × FVB)F1 (0/+), express half the amount of PrP as FVB, and have very long incubation times in spite of accumulating high levels of PrP^Sc^ in a long preclinical stage ([@b16]; [@b52]). On the other hand, FVB-Tg(PrP-A)4053 mice (Tg4053) that overexpress PrP transgenes have very short incubation times ([@b18]). FVB, 0/+, and Tg4053 mice were inoculated with RML prions (FVB-RML, 0/+-RML, and Tg4053-RML). FVB.129-*Prnp*^*tm1Zrch*^ mice (0/0) that lack PrP entirely, cannot be infected with prions ([@b15]) and do not develop disease, were also inoculated with RML prions to eliminate DEGs induced by prions that are not relevant to prion disease. Only one statistically significant DEG (*Itgam*) was found in 0/0 mice---reassuring us that the statistics and subtractive analyses of dynamically changing transcriptomes guided by prion biology worked effectively.

Thus, the eight mouse strain--prion strain combinations can be assigned to different groups to emphasize different aspects of disease and the DEGs generated by these groups can be used in subtractive comparisons to analyze discrete aspects of prion disease. Grouping B6-RML, B6-301V, B6.I-RML, B6.I-301V, and FVB-RML will emphasize DEGs induced by both prion strains and across incubation times; such shared DEGs are likely to reflect functionally important processes. The combinations also can be grouped according to prion strain for the identification of DEGs enriched in response to one strain versus the other (comparing B6-RML, B6.I-RML, and FVB-RML with B6-301V and B6.I-301V). Short incubation time combinations reflecting prion strain--PrP genotype interactions (B6-RML, B6.I-301V, and FVB-RML) also can be compared with long incubation time combinations (B6-301V and B6.I-RML). The genetically modified combinations (0/+-RML and Tg4053-RML) were used as biological filters whose incubation time differences reflected PrP concentration rather than PrP genotype.

Comparison of B6 and FVB mice inoculated with RML (B6-RML and FVB-RML) that do not have a large difference in prion incubation times served to filter out DEGs that presumably reflect mouse strain genetic polymorphisms (see [Supplementary Figure S1](#S1){ref-type="supplementary-material"} showing *Ccl12*, *Usp18*, and *Bst2* as examples of genes, the expression of which increased only in B6 mice).

Brains from three mice per group were harvested every 1, 2, or 4 weeks depending on the length of the incubation times as indicated in [Table I](#t1){ref-type="table"} (the idea was to have 8--10 sample comparisons across the incubation period). Comprehensive time course transcriptomic data sets were generated from each of the eight mouse strain--prion strain combinations using Affymetrix mouse array 430 2.0 chips (450 arrays, see Materials and methods and [Supplementary information](#S1){ref-type="supplementary-material"}).

The noise in this enormous amount of data includes both (1) biological noise due to environment-induced or stochastic variation among replicate, genetically identical individual mice that could obscure meaningful, but small, differences coming from different prion strains, alternative alleles of *Prnp*, differences in PrP concentration, and the resulting differences in incubation time and dynamics of pathological changes and (2) technological noise from variation in prion inoculation precision into the thalamus, sample preparation for array analysis, the array measurements themselves, and other factors. The majority of transcripts do not change their expression patterns as a result of prion disease, though some could be associated with prion disease despite no expression change---*Prnp* is the best-known example. The transcripts that are differentially expressed can also show different temporal patterns dependent on the mouse strain--prion strain combinations. The challenge here is to reliably detect initially small changes superimposed on a large more constant background. We developed an effective data analysis framework that can extract core prion-related signatures from such noise-corrupted data by resolving the noise-related problems. To cancel out responses caused by intracerebral inoculation and aging of the mice, we performed microarray analysis of age- and genotype-matched control mice inoculated with brain homogenates from normal mice at each time point; differential mRNA expression at each time point in each mouse--prion combination reflected subtraction of expression from the corresponding control mice. This minimized both biological and technological noises.

We developed a statistical method that effectively identified a core gene set, the expression levels of which were changed similarly across multiple mouse--prion combinations. The identification of this core gene set reduced the whole genome-scale data down to a smaller data set with potential prion disease association. Our method to identify shared expression patterns by integrating multiple mouse strain--prion strain data allowed the detection of differential signals that were marginal in some individual combinations but significant when considering all combinations together. Although analysis of DEGs using mRNA prepared from whole brain dilutes expression signals from individual brain regions, this integration-based gene selection compensates by its biological focus on changes that are relevant to the progression of pathology and prion replication. That is, this method can reliably select as DEGs the genes with marginal *P*-values (close to the cutoff) due to small expression changes (e.g. fold change=1.5) over time in the individual mouse--prion combinations by producing significant overall *P*-values (\<10^−3^) when the individual marginal *P*-values in multiple mouse--prion combinations were combined (details of the method described below). Using this method, we found that the overall *P*-values for such transcripts tend to be smaller than those of the transcripts that showed inconsistent temporal expression patterns (e.g. changed in some combinations and not changed in the others or changed in opposite directions) across the multiple mouse--prion combinations.

Shared DEGs in prion disease
----------------------------

To identify genes involved in essential processes related to prion pathogenesis, we first focused on the five prion strain-mouse strain combinations (B6-RML, B6.I-301V, B6-301V, B6.I-RML, and FVB-RML) that reflect *Prnp* allele- and prion strain-dependent short and long incubation times with normal levels of prion protein ([Figure 1](#f1){ref-type="fig"}). We developed a novel statistical method (see Materials and methods and [Supplementary information](#S1){ref-type="supplementary-material"} for further details) to identify the genes that are differentially expressed and also whose differential expression patterns are shared in the five combinations. We identified 333 DEGs (representing 428 probe sets, overall *P*\<10^−3^; see [Supplementary Table S1](#S1){ref-type="supplementary-material"} for the complete list) with shared temporal patterns of differential expression in the five core mouse--prion combinations. As will be presented later, these shared DEGs were also evaluated in 0/+ and Tg4053 mice where long and short incubation times are dependent on PrP concentration rather than on prion strain--PrP allotype interactions. Profiles for the top 20 shared DEGs with the lowest *P*-values (highest statistical significance for dynamic changes in prion disease) and for the bottom 20 DEGs at or near *P*=10^−3^ (lowest statistical significance) are shown in [Figures 2A and B](#f2){ref-type="fig"}. These profiles illustrate the range and patterns of shared expression across the five mouse--prion combinations used to identify shared transcripts as well as in 0/+ and Tg4053 mice inoculated with RML. The 333 shared DEGs did not change their levels in RML-inoculated 0/0 mice---supporting the contention from other subtractive analyses that these are reflections of the prion disease process.

Many of the highly significant DEGs had been identified in previous transcriptomic studies on differential gene expression in prion-diseased mice ([@b7]; [@b74]; [@b97], [@b96]; [@b11]; [@b81]; [@b82]). For example, of the top 20 DEGs in our study all but two (*Ifit1* and 0610011I04Rik) had been identified previously in at least one mouse strain--prion strain combination in one or more microarray studies. In contrast, only 9 of the bottom 20 genes of the core 333 gene list were found in previous studies ([Figure 2B](#f2){ref-type="fig"}). Asterisks on the gene labels in [Figures 2A and B](#f2){ref-type="fig"} indicate DEGs unique to this study. Overall, about half---178 of the 333 genes that we classified as shared---had not been identified previously as differentially expressed in prion-infected mice; only 11 of these were downregulated ([Supplementary Table S1](#S1){ref-type="supplementary-material"}). Microarray data were validated using RT--PCR for 59 of the 333 shared genes as shown in [Supplementary Figure S2](#S1){ref-type="supplementary-material"}. These shared DEGs were used as the basis for construction of hypothetical dynamic protein interaction networks for integration with pathological changes and PrP^Sc^ accumulation throughout the incubation period.

Integration of data from genetically modified mice to assess functional significance of DEGs
--------------------------------------------------------------------------------------------

We examined the effects of PrP concentration on differential expression patterns in prion infection. These data can be useful, for example, in discriminating DEGs that may be involved in prion replication from those responsible for neuron dysfunction and death, and in distinguishing non-pathogenic responses to PrP^Sc^ accumulation from those likely to be responsible for clinical disease. Mice heterozygous for the null allele of *Prnp* (0/+) have very long incubation times. Although the rate of accumulation of PrP^Sc^ is slower than that in wild-type mice, proteinase K-resistant PrP^Sc^ eventually reaches levels that are very similar to those in terminal FVB mice well before any signs of disease occur ([Figure 3A](#f3){ref-type="fig"}) ([@b16]; [@b52]). Even 40 weeks after infection no clinical signs are apparent in 0/+ mice even though the level of accumulation and distribution of PrP^Sc^ is comparable to that in FVB mice exhibiting significant clinical signs ([Figure 3A](#f3){ref-type="fig"}). This suggests that early-appearing DEGs in 0/+ mice might be more relevant to prion replication and less pathogenic host responses to PrP^Sc^ accumulation than to neurodegeneration and cell death. The dramatic increase in scrapie survival times of 0/+ mice in spite of carrying similar amounts of PrP^Sc^ as seen in terminal wild-type FVB mice for more than 200 days is an apparent consequence of the lower steady-state level of PrP^C^ in the brains of 0/+ mice---about one-half of that in wild-type mice. Consequently, the rate of accumulation of PrP^Sc^ in the brain is significantly less than in wild-type mice as is the rate of accumulation of neurological damage that ultimately results in clinical signs (see histoblots in [Figure 3A](#f3){ref-type="fig"} and in the Prion Disease DataBase (PDDB) website, <http://prion.systemsbiology.net>).

Among 333 shared DEGs gleaned from five prion--wild-type mouse strain combinations, 311 DEGs were changed in 0/+ mice (*P*\<0.05; [Supplementary information](#S1){ref-type="supplementary-material"}). A subset of the 311 DEGs shared by 0/+ were involved in key biological processes, as identified by analysis of their Gene Ontology (GO) annotations. These processes include complement activation, lysosomal proteases, cholesterol synthesis/efflux, glycosaminoglycan (GAG) metabolism, and sphingolipid synthesis/degradation ([Figure 3B](#f3){ref-type="fig"}). These results are consistent with these genes and their associated processes playing important roles in PrP^Sc^ replication and accumulation.

A significant question in prion disease is whether glial (both microglia and astrocytes) activation is triggered by accumulation of PrP^Sc^ directly or by neurodegenerative changes in neurons due to prion replication. The results in [Figure 3B](#f3){ref-type="fig"} show that genes associated with microglial proliferation and astrocytosis (*Cd14*, *Cd68*, *Gfap*, and *C1qb*) are not upregulated in very long incubation time 0/+ mice until ∼16 weeks (∼30% of the incubation period) when levels of PrP^Sc^ were first detectable in histoblots. Increased levels of these glial mRNAs occurred earlier (12 weeks) but after a greater portion of the 54% of incubation time had passed in their short incubation time partner ([Figure 3B](#f3){ref-type="fig"}). The appearance of glial DEGs in 0/+ mice well before any clinical signs or increase in the expression of genes indicative of neuronal damage implicates a direct response to PrP^Sc^, though signals from neurons can be ruled out.

Tg4053 mice have a short interval from inoculation to death and in conjunction with 0/+ mice could aid in discrimination of replication and pathogenesis. RML-infected Tg4053 mice overexpressing PrP showed significant changes in 125 (*P*\<0.05 in Tg4053) of the 333 DEGs in the shared set. Prominent shared DEGs in most of the key shared modules exhibited similar patterns in Tg4053 mice, though generally with differentials of smaller magnitude and closer in time to clinical illness and death than all other combinations of prion and strain (see [Figure 3](#f3){ref-type="fig"}). Tg4053 mice also showed a set of highly significant DEGs that were not seen in the other combinations. The 20 DEGs that were most significant in Tg4053 mice along with their expression in the other combinations are shown in [Figure 2C](#f2){ref-type="fig"}. Unlike 0/+ mice, Tg4053 mice (that overexpress PrP and die from RML scrapie at ∼8 weeks) show increases in a set of glial genes at 6 weeks (75% of its incubation time; [Figure 3B](#f3){ref-type="fig"}). The difference in dynamics of such genes is similar to the dynamics of PrP^Sc^ increase. Note the points at 16 weeks in 0/+, 12 weeks in FVB wild type, and 6 weeks in Tg4053 mice (see the arrows in [Figure 3A](#f3){ref-type="fig"} histoblots). Also we noted that the temporal patterns of such genes are similar to those of the genes involved in androgen/arachidonate metabolism and synaptic upregulated DEGs. Combining the observations in [Figure 3](#f3){ref-type="fig"}, we conclude that microglial activation and reactive astrocytic gliosis reflect responses to accumulation of PrP^Sc^ as well as to early degenerative changes in neurons, specifically synapse loss ([@b39]; [@b38]). Note that DEGs associated with neurodegenerative changes are not detected in our whole-brain data until disease is widespread.

Construction of dynamic networks: PrP^Sc^ accumulation
------------------------------------------------------

To associate the genes showing differential expression patterns with fundamental processes, we constructed hypothetical dynamic networks. Of the 333 shared DEGs, only 173 genes had sufficient protein--protein interaction or metabolic pathway information available in the literature for inclusion in one or more of our networks; 161 of these genes were included. Among the 161 'network\' genes, 117 genes were mapped to functional modules that have been previously associated with prion disease, whereas 44 genes were used to construct six novel functional modules (see [Table II](#t2){ref-type="table"} for selected genes for the novel modules; see below for details). The 172 genes that could not be so included have been grouped according to known functions (114 genes with prion-associated functions, 19 genes with novel functions, 27 genes with predicted functions, and 12 genes with no known functions; see also [Supplementary Table S1](#S1){ref-type="supplementary-material"} for details and [Supplementary Figure S8](#S1){ref-type="supplementary-material"} for distribution of the genes in the various groups) or shared temporal expression patterns ([Supplementary Figure S3](#S1){ref-type="supplementary-material"}). Interestingly, two shared DEGs with unknown functions (*AU020206* and *2310033F14Rik*) were identified from non-coding regions of the genome. It will be interesting to characterize their possible regulatory roles, if any, in prion disease.

To produce comprehensive networks, we relaxed the stringent *P*-value cutoff of 10^−3^ that was used for shared DEGs to include more transcripts (*P*\<0.01) showing similar differential expression patterns in two or more combinations. The inclusion of such genes allowed us to reconstruct well-connected networks thus describing a broad range of prion-related biological processes, which were still represented by the shared DEGs ([Supplementary information](#S1){ref-type="supplementary-material"}). For network construction, we clustered these genes into four groups representing four major pathological features of prion disease: (1) PrP^Sc^ replication and accumulation, (2) synaptic degeneration, (3) microglial and astrocyte activation, and (4) neuronal cell death. This was done by GO clustering of the genes using FuncAssociate ([@b5]) and then assigning the GO clusters to one or more of the four pathological feature groups, based on relationships between the corresponding GO terms and four pathological features ([Supplementary Table S2](#S1){ref-type="supplementary-material"} and [Supplementary Figure S4](#S1){ref-type="supplementary-material"}). For example, GO clusters of chemotaxis and complement activation were assigned to microglial and astrocyte activation. When the relationships were not obvious, such GO clusters were assigned to all groups of pathological features in which the GO processes can be possibly involved. For example, complement activation was assigned to both PrP^Sc^ replication and accumulation and microglial and astrocyte activation. Using the proteins encoded by selected genes assigned to each pathological group and their nearest interacting proteins, we constructed a hypothetical protein network describing the interactions in prion-related biological processes representing each pathological feature and their dynamic transitions. The interactions among the network nodes were obtained from the interaction databases, BIND (<http://www.bind.ca>) and HPRD (<http://hprd.org>). The network nodes were localized according to GO subcellular component information (lysosome, ER, PM, ECM, and so on), and the cell types (neuron, oligodendrocyte, microglia, or astrocyte) were assigned according to information from literature and public databases. Strikingly, assignment of cell types for 128 selected DEGs verified by cell type-specific patterns from *in situ* hybridization data of B6 mouse brains and image-based informatics annotation (for detailed methods, see [@b48]---describing the Allen Brain Atlas) was virtually completely consistent with the cell-type assignments in our hypothetical networks ([Supplementary Table S5](#S1){ref-type="supplementary-material"}). Some of the nodes and modules were assigned to microglia/astrocytes as these two cell types share gene expression of major components involved in immune responses (e.g. complement, TLRs, and cytokines). The protein node colors represent the increase (red) and decrease (green) in the expression of the corresponding genes at each time point in B6 mice inoculated with RML. The nodes were then clustered into functional network modules based on the similarity in their GO biological processes and their connectivity ([@b36]) (see [Supplementary Table S2](#S1){ref-type="supplementary-material"} for details). The arrows representing metabolic and signaling pathways were also added based on the KEGG pathways. As an example, a network of interacting proteins hypothesized to be involved in prion replication or responses to PrP^Sc^ accumulation is presented in [Figure 4](#f4){ref-type="fig"} with the dynamic changes in gene expression in B6-RML shown at 6, 10, 14, 18, 20, and 22 weeks. The highly significant (*P*\<10^−3^) DEGs are indicated by larger sized nodes, and DEGs unique to this study are indicated by asterisks. The underlined nodes represent the genes upregulated only in mice with short incubation times, and the dotted-underlined nodes represent the genes differentially expressed only in mice infected by RML prions. A histoblot showing distribution of proteinase K-resistant PrP^Sc^ in coronal sections including the hippocampal formation (approximately Bregma −1.5 to −2.2 mm) is included in each time point panel along with notation of clinical signs. All data collected in this study are available online (<http://prion.systemsbiology.net/>). It is important to emphasize that the networks discussed here are hypothetical and construction of alternatives using other methods is encouraged.

The network transitions show that dynamic perturbations of gene expression associated with biological processes occur in a specific order, which independently verifies the conclusion that neuropathological changes proceed in a stereotypical set of steps ([@b9]). Among the first detectable expression changes (10 weeks) were increases in mRNA levels of *C1qa/b* and *C3ar1* reflecting activation of microglia and astrocytes, one of the earliest detectable responses to prion infection ([@b44]) ([Figure 4B](#f4){ref-type="fig"}, module 1). Around the same time, the increased activities of lysosomal proteases were suggested by elevation of the lysosomal protease gene *Ctsc* ([Figure 4B](#f4){ref-type="fig"}, module 2): lysosomal proteases may have a role in degradation as well as formation of PrP^Sc^ ([@b98]). Changes within the lysosomal module became more obvious at later time points ([Figure 4C](#f4){ref-type="fig"}, module 2). The network also shows dysregulation associated with the synthesis, trafficking, and processing of cholesterol and sphingomyelin, two of the major components of lipid rafts where the initial steps of PrP^Sc^ replication are thought to occur ([@b80]). At 10 weeks, changes were detected in the expression of genes controlling trafficking and conversion of cholesterol ([Figure 4B](#f4){ref-type="fig"}, module 3) and sphingomyelin ([Figure 4B](#f4){ref-type="fig"}, module 4) ([@b75]). At 14 weeks, expression levels of cholesterol synthesis genes, such as *Mvk* and *Mvd*, were decreased, but expression of the cholesterol transporters or acceptors including *Abca1*, *A2m*, and *Apod* were increased (see the arrows in [Figure 4C](#f4){ref-type="fig"}, module 5). As will be discussed later, decreases in the expression of genes involved in cholesterol biosynthesis are particularly pronounced in mice infected with the RML prion strain.

Changes in sphingolipid metabolism, potentially leading to a decrease in galactosylceramide, which is found in PrP^Sc^ deposits ([@b45]), are evident by 18 weeks ([Figure 4D](#f4){ref-type="fig"}, module 4). The network also shows an increase in GAG metabolism, indicated by increased *Gusb* and *Hexb* mRNA levels, first detectable at 14 weeks ([Figure 4C](#f4){ref-type="fig"}, module 6) ([@b54]). This dynamic coupling of cholesterol, GAG, and sphingolipid pathways with PrP^Sc^ suggests, together with the findings from previous studies, that prion replication requires the close physical association among PrP^C^/PrP^Sc^, GAG, cholesterol, and sphingolipid on lipid rafts in the plasma membrane and during trafficking to the lysosome and endosome ([@b33]; [@b35]). Novel therapeutic approaches for prion disease can be developed that target these components simultaneously (see Discussion for details).

Dynamic network describing microglial/astrocytic activation
-----------------------------------------------------------

Similar to most infectious agents, PrP^Sc^ induces inflammatory responses by activating innate immunity through glial cells (microglia and astrocytes) in the brain ([@b65]; [@b82]). We constructed a protein network model using the shared DEGs that are associated with microglial/astrocytic activation ([Figure 5](#f5){ref-type="fig"}). This is consistent with neuropathological data showing that microglia are among the earliest responders to any form of neurodegeneration ([@b73]; [@b94]), that microglia proliferate and hypertrophy in prion disease in response to deposition of PrP^Sc^ ([@b93]), and that reactive astrocytic gliosis, which tends to follow activation of microglia, is induced by factors released from microglia ([@b40]; [@b59]; [@b58]; [@b62]). Transcriptome analysis suggests that the first apparent reactive changes (from 10 weeks in B6-RML) are activation of complement pathways by PrP^Sc^ ([@b44]; [@b79]; [Figure 5](#f5){ref-type="fig"}, module A), pattern recognition receptors (PRRs), and other receptors potentially responsible for PrP^Sc^ recognition and uptake ([Figure 5](#f5){ref-type="fig"}, module B). Lack of increased expression of innate immune system genes in 0/+ mice before 16--18 weeks is compatible with gliosis and expression of these genes in glia rather than neurons as it appears that little neuronal damage is seen at this stage ([Figure 5](#f5){ref-type="fig"}). Similarly, the kinetics of expression of innate immune receptors and their downstream cytokines relative to PrP^Sc^ accumulation suggest that these receptors may recognize proteins perturbed by prion infection, such as intraneuronal proteins and peptides released as a result of early synaptic changes, rather than carbohydrate moieties on PrP^S*c*^. Complement complexes and PRRs may be responsible for stimulating the production of cytokines, chemokines ([Figure 5](#f5){ref-type="fig"}, module C), and growth factors ([Figure 5](#f5){ref-type="fig"}, module D), as well as for astrocytic activation as indicated by increased expression of glial markers such as *Gfap* and P2RY receptors ([@b89]; [Figure 5](#f5){ref-type="fig"}, module E). Activation of endothelial cells through cytokines released from microglia and astrocytes would enhance migration of leukocytes from the blood and their differentiation into microglia ([Figure 5](#f5){ref-type="fig"}, module F). This possibility is supported by the increased expression of genes involved in the multistep processes of leukocyte extravasation: selectin ligands, adhesion molecules, chemokines and their receptors, integrins, transendothelial migration genes, and intracellular signaling molecules. Conversion of mononuclear leukocytes (blood monocytes) into microglia when they enter the brain is suggested by upregulation of *Csf1* ([Figure 5](#f5){ref-type="fig"}, module D). Most of these DEGs were shared by 0/+-RML mice, thus implying their potential importance in PrP^Sc^ replication, but indicating that these responses on their own are insufficient for the production of clinical signs. Although this might reflect a response to more rapidly accumulating PrP^Sc^, recruitment of microglial cells from blood also might facilitate PrP^Sc^ replication by increasing PrP^Sc^ trapping.

Networks highlighting neurodegeneration and cell death were also constructed and are presented and discussed as [Supplementary Figures S5 and S6](#S1){ref-type="supplementary-material"} and are presented on the PDDB website.

Novel network modules
---------------------

Our strategy identified many shared genes not previously associated with prion disease. Examining the recent literature for metabolic pathways in which these genes are involved, in conjunction with the similarity of their expression profiles, led us to hypothesize several novel modules with concerted changes of expression for closely related genes. The androgen metabolism module is illustrated in [Figure 6A](#f6){ref-type="fig"}. To our knowledge, this is the first report of potential involvement of androgen metabolism in prion disease. BZRP (translocator protein, 18 kDa) functions as an essential rate-limiting step toward mitochondrial biosynthesis of androgenic molecules, together with its endogenous ligand diazepam-binding inhibitor (*Dbi*) ([@b64]; [@b63]). The global stimulation of androgen biosynthesis pathway implies altered levels of neurosteroids in prion disease. In addition, the increased expression of *Cntf* as shown here and in a previous study ([@b57]) may suggest a link between perturbed androgen metabolism and glial activation in prion-infected brains as *Cntf* upregulation leads to reactive astrogliosis through the JAK/STAT pathway. A possible regulatory relationship between CKLFSF3 and androgen receptor has recently been reported ([@b90]). CKLFSF3 interacts directly with BLNK ([@b37]), further suggesting a tie between androgen metabolism and glial activation (see [Figure 5](#f5){ref-type="fig"}, module E). The temporal patterns of these genes were similar to those in cholesterol clearance ([Figure 3B](#f3){ref-type="fig"} and [Figures 4D--F](#f4){ref-type="fig"}, module 3), implying that dysregulated cholesterol metabolism also may be coupled to the perturbation of neurosteroid metabolism.

A second module with potential importance in prion disease involves iron homeostasis and heme metabolism. Concurrent upregulation was detected for genes involved in iron uptake, transport, storage, and heme degradation ([Figure 6B](#f6){ref-type="fig"}). These results are consistent with two recent *in vivo* observations: (1) increased levels of redox-active iron in scrapie-infected mouse brain ([@b43]; [@b2]) and (2) a stimulatory effect of redox iron on the conversion of PrP^C^ to PrP^Sc^ ([@b2]). The activation of the heme degradation pathway in the brain has been associated with cellular response to oxidative stress ([@b1]). Six DEGs (*Mgst1*, *Mt1*, *Mt2*, *Prdx6*, *Scara3*, and *Ucp2*) with protective functions against oxidative stress showed patterns of expression similar to those of iron heme metabolism genes, suggesting interaction between the two modules (data not shown). Iron homeostasis is essential for the maintenance of oligodendrocytes and myelin in brain ([@b21]; [@b61]), and its dysregulation may be related to demyelination in prion disease ([@b88]; [@b3]). Indeed, our data show significant changes in the expression of genes encoding proteins involved in myelination (*Padi2*, *AI838057/Met*, and *Nupr1* ([@b67]; [@b56]; [@b60]).

A third module of interest from our data is arachidonate/prostaglandin metabolism, in conjunction with phospholipid metabolism and calcium signaling pathway. Shared DEGs that are involved in biosynthesis of proinflammatory prostaglandins and leukotrienes from arachidonate and their clearance show shared patterns of increased expression ([Figure 6C](#f6){ref-type="fig"}). Activation of this module should prompt a search for excessive production of these pro-inflammatory metabolites in prion-infected brains ([@b42]). Interestingly, upregulation of COX-1 (*Ptgs1*) has been observed in post-mortem brains of CJD patients ([@b23]). Moreover, it was recently shown that coactosin-like 1 (*Cotl1*) can also upregulate ALOX5 (5-lipoxygenase) activity and LTA~4~ production in a Ca^2+^-dependent manner ([@b72]). Changes in arachidonate metabolism may be linked with the perturbation of phosphatidylinositol metabolism and calcium signaling pathway through AMP deaminase ([Figure 6C](#f6){ref-type="fig"}).

Five additional processes (demyelination-neurogenesis, hematopoiesis, chondrogenesis, DNA damage repair, and uracil/thymidine catabolism), represented by 20 shared DEGs, may also be associated with prion disease (see [Table II](#t2){ref-type="table"} for selected modules and genes and [Supplementary Table S1](#S1){ref-type="supplementary-material"} for the complete list). In addition, among 39 DEGs with no known functions, 27 genes can be potentially related to various functional modules mentioned above through predictions using protein domain information or indirect experimental evidence (for example, *E030018N11Rik* is predicted to be involved in phospholipid metabolism because of its protein sequence similarity to ITPRIP family, including inositol 1,4,5-triphosphate receptor interacting protein; see [Table III](#t3){ref-type="table"} for truncated list of predicted functions and associated genes and [Supplementary Table S1](#S1){ref-type="supplementary-material"} for the complete list).

In short, novel associations revealed in our study can be used to generate testable hypotheses for events in prion disease. Searching for associations among subgroups of mouse strain--prion strain combinations is also worthwhile. The complete list of functional modules enriched with 333 shared DEGs is shown in [Supplementary Table S1](#S1){ref-type="supplementary-material"}.

Incubation time- and prion strain-associated DEGs
-------------------------------------------------

Grouping mice according to differences in incubation times among the five core prion--mouse combinations that were used to define shared DEGs identified 55 genes, the expression of which was significantly increased (*P*\<10^−4^) in the three short incubation time combinations (B6-RML, B6.I-301V, and FVB-RML) but showed no significant change in mice with long incubation times (B6-301V and B6.I-RML). Statistical methodologies for grouping DEGs by incubation time or prion strain are provided in [Supplementary information](#S1){ref-type="supplementary-material"}. Examples are shown in [Figure 7](#f7){ref-type="fig"}. In total, 27 of these short incubation time DEGs showed increased expression in scrapie-infected mice and 28 were downregulated ([Supplementary Table S3](#S1){ref-type="supplementary-material"}). There were no genes that were differentially expressed only in the long incubation time combinations. It is important to stress that a long incubation time in itself does not preclude detecting differential expression of the short incubation time DEGs. RML-infected 0/+ mice, which have very long incubation times, show significant scrapie-induced changes in 5 of the 55 'short incubation time\' DEGs (*P*\<0.05 in 0/+-RML). Among the 55 genes showing differential expression in short incubation time combinations, we found decreased expression of four genes (*Cycs*, *Ndufa10*, *Cox6b1*, and *Atp5j2*) involved in ATP biosynthesis in the oxidative phosphorylation pathway ([Supplementary Figure S7A](#S1){ref-type="supplementary-material"}), and increased expression of five genes (*Chst2*, *Ndst1*, *Sdc3*, *Sulf2*, and *Galnt6*) that mediate biosynthesis of various GAGs ([Figure 4](#f4){ref-type="fig"}, see also [Supplementary Figure S7B](#S1){ref-type="supplementary-material"}). The increased levels of *Ndst1* and *Sulf2* and decreased expression of *Hs6st2*, whose protein catalyzes the 6-O-sulfation of heparan sulfates (a function opposite to that of SULF2) may redirect metabolic flux to 2-O-sulfated heparan sulfate, an entry point to the GAG degradation pathway ([@b66]). This finding is consistent with the potential roles of GAG in prion pathology as membrane receptors for PrP^Sc^ as noted earlier and is supported by the effect of drugs interfering with PrP^Sc^--GAG interactions, such as Tilorone ([@b53]) and Copaxone ([@b24]) on increasing the incubation time of prion disease. It is important to stress that the differences between short and long incubation time DEGs are not absolute, but rather quantitative differences in expression between the two groups. Thus, our data suggest that perturbation of mitochondrial ATP synthesis and lysosomal GAG biosynthesis are two important factors that can contribute to accelerated progression of prion disease. We also found that the remaining 55 short incubation time DEGs are involved in various signaling pathways such as calcium signaling (e.g. *Camk4*), phosphatidylinositol signaling (e.g. *Itpr1*), and MAPK signaling pathways (e.g. *Ptprr*) as well as in adhesion (e.g. *Pvrl3*), axon guidance (e.g. *Ntng1*), and apoptosis (e.g. *Cflar*).

Grouping the B6 and B6.I congenic strains according to prion strain identified 39 DEGs that were significant only in RML inoculated mice. In total, 19 of these genes were elevated and 20 showed decreased expression. These genes are indicated in [Supplementary Table S4](#S1){ref-type="supplementary-material"} and [Figure 7](#f7){ref-type="fig"}. No DEGs were found that were specific to 301V inoculated mice. Interestingly, 7 of the 20 genes with decreased expression (*Hmgcs1*, *Nsdhl*, *Cyp51*, *Sc4mol*, *Idi1*, *Sc5d* and *Sqle*) are involved in cholesterol biosynthesis, showing consistent reduction in RML-infected mice but no significant changes in 301V-infected mice ([Figure 4](#f4){ref-type="fig"}, module 3). Four of these genes, *Cyp51*, *Sc4mol*, *Nsdhl*, and *Sqle* show similar expression patterns in normal B6 mouse brain as assessed using the NeuroBlast function of the Allen Brain Atlas ([@b48]). The correlation in distribution among the four was particularly strong in the thalamus (for coronal sections, correlation coefficients with *Cyp51* for *Sqle*=0.85, for *Sc4mol*=0.76, and for *Nsdhl*=0.81).

Discussion
==========

Our goal in using whole-brain mRNA expression data from diverse mouse strain--prion strain combinations as the core of a systems analysis of prion disease was to identify and assign function to interacting networks involved in prion replication and pathogenesis. The earliest detectable neuropathological events following intracerebral inoculation with prions are conversion of PrP^C^ to PrP^Sc^ in neuronal membranes, axonal transport of PrP^Sc^ to adjacent neurons, accumulation of PrP^Sc^ in axon terminals, and transynaptic spread of PrP^Sc^ formation in the plasma membrane of the postsynaptic neurons. Accumulation of PrP^Sc^ in synaptosomes is followed within a week by abnormal distribution of synaptic vesicles in presynaptic boutons, decreased evoked release of neurotransmitters by synaptosomes ([@b9]), presynaptic bouton degeneration and both atrophy and loss of dendrites ([@b38]). These neurodegenerative events can be highly localized early in disease, but, in combination with the resulting release of PrP^Sc^ into the extracellular space diseased cells appear to attract and activate microglia, the first responders to neurodegeneration ([@b73]). Activated microglia may be a major factor causing nerve death in prion diseases ([@b27]; [@b69]). Although the mechanism of microglial-mediated nerve cell death is not fully understood, one possibility is overactivation of microglia secondary to exposure to PrP^Sc^ ([@b6]).

The mechanism of nerve cell death is unknown; however, multiple pathogenic mechanisms have been proposed, including: (1) deafferentiation secondary to extensive axon terminal degeneration ([@b13]; [@b12]); (2) decreased binding affinity of receptors for neurotransmitters and trophic factors required for neuronal viability secondary to accumulation of large amounts of PrP^Sc^ in neuronal plasma membranes ([@b47]; [@b87]; [@b95]); and (3) selective degeneration of GABAergic inhibitory inputs to neurons leading to excitatory neurotoxic nerve cell death ([@b31], [@b30], [@b32]). Of these putative mechanisms, the continuous conversion of PrP^C^ to PrP^Sc^ in cholesterol-rich membrane rafts followed by continuous endocytosis and accumulation of large amounts of protease-resistant PrP^Sc^ in lysosomes when large numbers of neurons degenerate ([@b10]; [@b9]) most likely accounts for a significant amount of nerve cell death. However, these putative causes of neuronal death are not mutually exclusive and, indeed, may all contribute to late stage nerve cell death both in prion disease acquired by infection with prions and spontaneous (sporadic) and familial prion disease.

What does this brief review of our understanding of neurodegeneration in CJD and scrapie tell us? First, neurodegeneration proceeds in a stereotypical set of steps from accumulation of PrP^Sc^ in cholesterol-rich lipid rafts to early synapse degeneration to nerve cell death. Second, the data supporting such degeneration sequence are derived from research in multiple laboratories that have viewed neurodegeneration in prion diseases from different perspectives and with different preconceptions about neurodegeneration in prion disease. Our comprehensive and independent systems analysis provides gene expression that correlates very well with pathological information in the whole-brain studies of prion disease and may aid in organizing the current abundance of data fragments into a coherent pathogenic model of neurodegeneration. The meshing of our networks constructed using transcriptome data with defined pathological processes increases our confidence that systems analyses provide a valid tool for hypothesis development.

The most important feature of the dynamic networks is that the transitions in gene expression precede clinical signs and PrP^Sc^ accumulation. For example, perturbations of several network modules, such as complement activation ([Figure 4](#f4){ref-type="fig"}, module 1), lysosomal protease activity ([Figure 4](#f4){ref-type="fig"}, module 2), and GAG metabolism ([Figure 4](#f4){ref-type="fig"}, module 6) are evident earlier than the clinical signs and widespread PrP^Sc^ accumulation. It is also important to stress that changes reflecting early synaptic loss that is first detectable histologically in the thalamus are not detected until later in mRNA prepared from whole brain due to signal dilution. The dynamic changes in each of these perturbed network modules precede, but track perfectly with, clinical signs and PrP^Sc^ accumulation, indicating that the perturbations of biological processes in the network modules are potential contributors to PrP^Sc^ accumulation and the resulting clinical signs. It should be noted that virtually all neuropathological, pathophysiological and clinical data to date have been correlated with protease-resistant rPrP^Sc^ and have not taken into account protease-sensitive sPrP^Sc^. In the early stages of infection of mice with prions, ∼80% of the total PrP^Sc^ is sPrP^Sc^ ([@b78]). At ∼60 days postinoculation (d.p.i.) when early occurring dendritic atrophy begins, about twice as much sPrP^Sc^ is found in the brain than rPrP^Sc^. Whether or not sPrP^Sc^ perturbs biological processes presented in our hypothetical protein networks remains to be determined.

Examination of co-expression patterns can lead to development of testable hypotheses for networks important for prion pathogenesis. Our results suggest that delay or inhibition of prion replication and accumulation might be achieved by targeting some combinations of cholesterol homeostasis, GAG metabolism, and/or sphingolipid metabolism ([Figure 4](#f4){ref-type="fig"}). Several drugs can inhibit prion replication, all of which target a biological process involved in one of these three network modules: (1) GAG depletion (chlorate, heparinase III) ([@b26]; [@b4]); (2) inhibition of GAG\'s binding to PrP^C^ (quinacrine) ([@b53]); (3) disruption of lipid rafts through cholesterol redistribution (quinacrine) ([@b46]) and (4) inhibition of cholesterol biosynthesis (desipramine) ([@b46]). However, our systems approach that builds hypothetical dynamic relationships among these biological modules involved in prion replication delineates their temporal coupling. We predict that for more efficient inhibition of prion replication, GAG-, cholesterol- and sphingolipid-related processes should be targeted simultaneously. In support of this prediction, a cocktail of a synthetic chimerical compound (quinacrine+desipramine) for disruption of lipid rafts together with simvastatin for inhibition of cholesterol synthesis was reported to synergistically increase anti-prion activity ([@b46]).

Perturbations of pathways more prominent with one prion strain than another also might provide clues on mechanisms of targeting to specific regions of the brain or cofactors involved in the conversion of PrP^C^ to PrP^Sc^. For example, examination of DEGs prominent in short incubation time strains revealed a decreased expression for genes involved in ATP biosynthesis in the oxidative phosphorylation pathway and increased expression of GAG biosynthetic genes. Expression of genes involved in cholesterol biosynthesis was significantly downregulated in RML prion-infected mice, but showed little change in mice inoculated with 301V prions. Most work toward developing anti-prion therapies has been carried out in short incubation time systems using RML or closely related prion isolates, suggesting that therapies for one prion strain or one host genotype may not be effective in other situations. The same considerations will probably hold in humans with different phenotypic types of prion diseases emerging from different prion mutations and as such indicates the importance of the emerging personalized medicine---treating individuals as individuals and not as a member of large populations ([@b68]).

Another use of the systems medicine approach is to aid in the identification of genes that affect the pathogenesis of prion disease. For example, several studies have mapped genetic modifiers of prion susceptibility and incubation time ([@b71]; [@b86]; [@b50]; [@b51]; [@b55]). Prion-specific DEGs that are located in chromosomal regions containing modifier genes are priority candidates for the genes underlying modulation of prion incubation time.

Genetically modified mice whose prion incubation times reflect levels of PrP expression help discriminate among genes relevant to prion replication, pathological changes, and clinical disease. It is striking that disease progression is slow in the heterozygous 0/+ mice, although PrP^Sc^ accumulates to levels comparable to those in diseased wild-type mice long before clinical signs occur. Most (311/333) DEGs shared among B6-RML, B6-301V, B6.I-RML, B6.I-301V, and FVB-RML also show similar patterns of change in 0/+ mice. The onset of differential expression occurs later in 0/+ mice than in the other combinations, presumably reflecting the reduced supply of PrP^C^ for conversion to PrP^Sc^, but, in most cases, the elevated or reduced levels of DEGs persists for a much greater proportion of the incubation period. These results suggest that fundamental processes are shared among 0/+ mice and our core panel, and the long incubation time due to reduced PrP^C^ levels reflects the time required for accumulation of sufficient neurological damage. Degradation of pathogenically relevant PrP^Sc^ from the brain could also be more efficient in 0/+ mice ([@b78]) and thus account for some of this effect.

On the other hand, RML-infected Tg4053 mice, overexpressing PrP, showed significant changes in 125 of the 333 DEGs in the shared set. Prominent shared DEGs in most of the key shared modules exhibited similar patterns in Tg4053 mice, though generally of smaller in magnitude and closer in time to clinical illness and death than all other combinations (see [Figure 3](#f3){ref-type="fig"}). This suggests that similar pathological responses and processes associated with prion replication are occurring in PrP-overexpressing mice in accord with the similar end-stage pathology typical for RML prion-infected mice. Although perturbed networks and modules in the other combinations were generally shared by Tg4053, there was also a unique set of highly significant DEGs in these transgenic mice ([Figure 2C](#f2){ref-type="fig"}). The very short incubation time of Tg4053 reflects the increased supply of PrP^C^ for conversion to PrP^Sc^ and expression of the Tg4053-specific DEGs changed soon after infection. The Tg4053 set may reflect networks perturbed by prion replication. Alternatively, the overexpression of PrP may induce novel replication and disease pathways and affect cell types that are not prominent in the other mouse strain--prion strain combinations. It is important to stress, for both Tg4053 and the other combinations, that changes in the levels of expression can reflect changes in transcription, changes in mRNA turnover, loss of specific cell types, or loss of specialized structures such as synapses that may harbor select mRNAs. It is likely that our results reflect all of these mechanisms. For example, the increased levels of glial DEGs in the brain can reflect both activation of the cells and cell proliferation or influx of microglial precursors as suggested by the perturbation in the leukocyte extravasation module ([Figure 5](#f5){ref-type="fig"}). It is also worth noting that the inconsistent and large changes in expression that are seen in many genes after clinical disease appears are likely to reflect cell death and nonspecific changes due to illness.

Although there is clear correspondence between pathological events and changes in gene expression in relevant networks and modules, it is not clear which, if any, of the changes are specific to prion infection. Not surprisingly, many of the shared prion DEGs have been seen in other neurodegenerative diseases, where similar pathological events such as gliosis, synaptic degeneration, and neuron loss occur. Dynamic analysis of changes in gene expression during the course of neurodegenerative diseases in humans is difficult, but analyses similar to ours have been performed in transgenic mouse models. Several previous studies on mice overexpressing Alzheimer\'s amyloid precursor protein (APP) demonstrated involvement of similar networks. A limitation of these studies is the failure of Tg(APP) mice to recapitulate the neurofibrillary tangles and neuron loss of Alzheimer\'s patients. Particularly informative are the kinetic analyses by Y Wakutani and P St George-Hyslop (personal communication) on the perturbation of inflammatory pathways as amyloid accumulates in Tg(APP)CRND8 mice; these changes are similar to those seen in prion infection. Although no appreciable neuron loss occurs in TgCRND8 mice, synaptic loss and behavioral changes are observed. Overall, of 86 DEGs observed in TgCRND8 mice, 37 were observed as shared in our study (see [Supplementary Tables S1 and S2](#S1){ref-type="supplementary-material"}) were seen as RML prion strain-enriched DEGs. Notable differences in DEG sets between prion-infected mice and TgCRND8 include the absence of PRR-related genes in TgCRND8 mice, whereas complement genes and glial markers are shared between the two disease models. Although similar processes, such as lipid metabolism, were perturbed in both systems, individual DEGs or the direction of changes for the same DEGs often differed. Most interesting examples are genes involved in cholesterol biosynthesis: these genes were decreased in RML prion-infected mice, whereas they were upregulated in TgCRND8 mice. Whether any of the DEGs that appear to be markers for prion infection actually are specific for prion disease will require further investigation. It is striking that even including our novel modules, nearly one-third of our shared DEGs could not be assigned to a hypothetical prion disease network. Such genes represent the 'dark genes\' of prion disease and suggest that all diseases will be far more complex than initially thought. This is a compelling argument for using the global or comprehensive analyses of systems approaches.

Although associating DEGs to pathological events is relatively straightforward, identifying genes as specifically involved in or perturbed by the process of conversion of PrP^C^ to PrP^Sc^ is more difficult. Addition of brain homogenate greatly facilitates the conversion of purified PrP^C^ *in vitro* protein-mediated cyclic amplification reactions ([@b84]) and an unknown factor that binds to a C-terminal region of PrP may be limiting for cross-species transmission as a facilitator of conversion ([@b41]). Various prion infection-specific DEGs have been reported in N2a cells, which do not exhibit severe cellular abnormalities due to prion replication. However, systematic analysis of N2a sublines independently infected with scrapie prions did not reveal any set of shared DEGs indicative of prion infection that were common to all sublines ([@b19]). Although this is likely due to the instability and aneuploidy of N2a cells, the possibility that gene expression is only moderately perturbed by the conversion process must be considered. The fact that mRNA levels for arguably the most important molecule in prion disease, PrP, do not change during the course of infection was confirmed in this study (difference of the *Prnp* mRNA levels between infected and normal brains were not significant). This lack of change originally led some to conclude that PrP was not central to disease ([@b20]). Other post-translational changes, such as elevation of the Notch intracellular domain that has been demonstrated to play a role in prion disease ([@b38]), would not be detected in our study. Similarly, levels of the PrP-related protein Shadoo have been reported to decrease in prion-diseased mice ([@b91]), but expression of its mRNA (*Sprn*) is unchanged; the relevance of changes in Shadoo levels to prion disease is as yet uncertain.

A systems approach to discover early, reliable diagnostic markers has drawn significant attention in prion disease because definitive diagnosis currently requires post-mortem immunological analysis of brain tissues ([@b77]; [@b83]; [@b29]). As an alternative, early and reliable blood assays would be very desirable, especially to prevent the spread of the disease through blood transfusion or consumption of prion-infected animal meat. Currently, advanced blood assay technologies still focus on the detection of very low levels of PrP^Sc^ in blood. Cyclic amplification of the PrP^Sc^ protein from blood of affected animals has been achieved ([@b76]), but sensitivity is as yet too low (only 60% of prion-infected animals tested positive) for routine application to preclinical diagnosis. In this regard, the shared DEGs uniquely associated with prion pathophysiology and secreted into the blood offer new opportunities for the identification of diagnostic marker candidates for robust blood assays, as some of the expression changes are expected to be reflected as changes in the levels of disease-perturbed brain proteins secreted into the peripheral blood. Preliminary observations suggest that this will be a powerful approach to early diagnosis of prion disease. H Yoo and L Hood (unpublished observations) used selected prion-specific DEGs as biomarker candidates in conjunction with mass spectrometry-based proteomics analyses to identify multiple secreted proteins as potential diagnostic serum biomarkers of prion disease. The important point is that a systems approach to disease will, through the formulation of testable hypotheses, lead to deeper mechanistic insights into the disease process and will as well lead to powerful new approaches to early (preclinical) diagnosis and therapy (using drugs to re-engineer disease-perturbed networks to make them behave in a more normal manner---or at least abrogate the more deleterious aspects of their function). In a more conventional approach to therapy, this network analysis will reveal key nodal points that may themselves become targets for drugs. In either case, the systems approach to disease does open up powerful new approaches to the identification of targets for drug therapy.

It is clear that these network studies reflect the dynamics of the prion infectious process---at this time they have not provided insights into the initiating mechanism(s) of disease. We should stress that there are not a sufficient number of informative time points during the early stages of the prion disease to identify the initial changes induced by infection. Moreover, the dilution of signal from these earliest changes that would have occurred initially in a small number of cells might well be beyond the resolution of these studies conducted on whole brain, suggesting that early samples of thalamus, where prion replication is first detected, may be more informative. In spite of this, we have detected dynamically changing series of brain networks that have relevance to the changing pathophysiology of the disease. We plan to follow up these studies with the infection of CNS stem cell-containing brain neurospheres *in vitro* ([@b28]). In these cell lines, we should be able to detect very early events, at the expense of losing the context of the intact brain and its multiplicity of cellular interactions.

We have demonstrated here the power of comprehensive, global approaches to systems as complex as prion disease, even when the data sets are restricted to gene expression profiles, and involve whole brain. The efficacy of using several strain combinations, prion and genetic backgrounds as a biological filter to deal with signal-to-noise issues and identify the network signals that are important for various disease-related processes is a striking lesson from our study. The new modules that have been connected to the disease, the strong alignment of the specific pathogenic processes with network changes, and the range of novel and sharpened hypotheses illustrate the power of this approach. We have confidence that with the addition of other data types, the attribution of network processes to brain regions and cell types, and the specific testing of hypotheses suggested here, that the systems medicine of prion disease (and other neurodegenerative diseases) will advance rapidly.

Materials and methods
=====================

Mice and scrapie infection
--------------------------

B6, B6.I, FVB, 0/+, 0/0, and Tg4053 mice were used. Female mice (C57BL/6 and others) were inoculated intracerebrally at 5 weeks of age with 10 μl of 10% brain homogenate from clinically ill mice or normal control mice. Two prion strains were used: RML and 301V. Mice were killed at the intervals indicated in [Table I](#t1){ref-type="table"} for RNA preparation and brain histoblots. Clinical signs at the time of killing were noted.

RNA preparation and microarray analysis
---------------------------------------

Total RNA was extracted from each mouse brain using TRIZOL reagent (Invitrogen, USA), was treated with *DNase I* (Ambion), and further purified with RNeasy columns (Qiagen, USA). Quality of RNA samples was evaluated by using BioAnalyzer (Agilent, USA). Here, 5 μg of total RNA was reverse transcribed and followed by generation of double-stranded cDNAs. The resulting double-stranded cDNAs were purified and biotinylated to cRNAs. The labeled antisense cRNAs were fragmented and hybridized to GeneChip Mouse Genome 430 2.0 Array (Affymetrix, USA), which contains 45 000 probe sets. The hybridization was carried out for 16 h at 45°C. The arrays were washed and stained with streptavidin phycoerythrin using a GeneChip Fluidics Station 450 (Affymetrix) and scanned using a GeneChip scanner 3000 (Affymetrix). The scanned images of the arrays were converted and imported into the ISB\'s Systems Biology Experiment Analysis System (SBEAMS) for array data normalization and further analyses.

Identification of shared DEGs across the five prion--mouse combinations
-----------------------------------------------------------------------

To identify the genes involved in essential processes related to prion pathogenesis, we identified the DEGs with shared differential expression patterns in five prion--mouse combinations (B6-RML, B6.I-301V, B6-301V, B6.I-RML, and FVB-RML). The following method was applied: (i) log2 median ratios at each time point were computed in all five core combinations; (ii) the time points in each prion--mouse combination are normalized by its incubation time, and the log2 median ratios for each gene at the normalized time points are then scaled into those with zero mean and unit variance; (iii) these scaled median ratios from the five combinations were combined, and a smoothing line was then fit using super smoothing method ([@b25]) to the combined median ratios to compute a goodness of fit measure, a normalized ratio of sum of squared regression to sum of squared error ([Supplementary information](#S1){ref-type="supplementary-material"})---for a gene whose normalized temporal expression patterns are well-correlated, a high goodness of fit measure is produced; (iv) to perform an empirical statistical hypothesis testing, a control data set was generated using Monte Carlo simulation by randomly sampling the five combination data ([Supplementary information](#S1){ref-type="supplementary-material"}); (v) goodness of fit measures were then computed for the genes in the randomly sampled data set---the computed goodness of fit measures are not large because they should not be systematically correlated in the random data; (vi) a null hypothesis distribution (pdf(H0)) was then empirically driven using Gaussian kernel density estimation for the computed goodness of fit measures; and (vii) a *P*-value of a gene being correlated by chance across the five combinations was then calculated using pdf(H0) by one-sided test of the corresponding goodness of fit measure computed in step (iii) ([Supplementary information](#S1){ref-type="supplementary-material"}). A gene with a small *P*-value shows well-shared patterns across the five core combinations. In addition to the correlation in temporal expressions, the shared DEGs should also be differentially expressed in all combinations ([Supplementary information](#S1){ref-type="supplementary-material"}). Thus, *P*-values of genes being differentially expressed in all five combinations were computed by combining the five *P*-values ([Supplementary information](#S1){ref-type="supplementary-material"}). Finally, both *P*-values for correlation and combined *P*-values for differential expression are then combined using Stouffer\'s method ([@b36]), resulting in the overall *P*-values of genes showing shared differential temporal patterns. A gene with a small overall *P*-value shows well-shared differential patterns. To stringently identify the shared DEGs, we selected shared DEGs using a cutoff for the overall *P*-values of 10^−3^. Then, we further removed potential false positives as follows: for each selected shared DEG, (1) the maximum *P*-value (*P*~max~) of those computed for differential expression in the five mouse--prion combinations (PB6-RML, PB6.I-301V, PB6-301V, PB6.I-RML, and PFVB-RML; [Supplementary information](#S1){ref-type="supplementary-material"}) was computed; (2) the maximum absolute fold changes in the individual combinations (*T*~max~(B6-RML), *T*~max~(B6.I-301V), *T*~max~(B6-301V), *T*~max~(B6.I-RML), and *T*~max~(FVB-RML)) were computed; and (3) the selected genes were considered and removed as false positives if at least one of the five *P*~max~ values was larger than 0.1 and at least one of the five *T*~max~ values from the five combinations was smaller than 1.5 at the same time.

Typical time course analyses mainly detect differential expression in the individual time course data ([Supplementary information](#S1){ref-type="supplementary-material"}). Unlike these methods, our method focuses on detecting shared patterns among differential expression from multiple time course data sets differing in numbers of time points, sampling intervals, and time spans at the expense of ignoring differential expression not common in all multiple time course data sets.

Identification of incubation time- and prion-specific genes
-----------------------------------------------------------

To identify the genes involved in biological processes that are activated only in mice with short incubation times and also a particular prion strain, the following method was applied: (i) a training set of the genes showing incubation time-specific (or RML-specific) differential expression was identified by examining false positives that were removed from the shared DEGs selected with a relaxed cutoff of *P*\<0.01; (ii) after smoothing expression profiles of the genes in the training set using a moving average method (window size=5), the reference temporal profiles were defined for the genes in the training set as the median profile of smoothed log2 temporal ratios; (iii) for each gene, the correlation (also *t*-statistic value) of the smoothed log2 temporal profile with the reference profile was computed; (iv) as done in the previous empirical statistical hypothesis testing, the null hypothesis distribution was then estimated after generating a randomized control data set and computing the correlation and *t*-statistic values with the reference profile; and (v) using *pdf*(H~0~), a *P*-value was computed for each gene. Finally, a set of incubation time-specific (or RML-specific) genes was identified using a stringent cutoff (*P*\<10^−4^). We also further removed potential false positives when a *P*-value for differential expressions in short incubation time (or RML) combinations was at least larger than 0.1 and also a *P*-value in long incubation time (or FVB) combinations was at least less than 0.1, respectively. See further details in the [Supplementary information](#S1){ref-type="supplementary-material"}.

Supplementary Material {#S1}
======================

###### 

Supplementary Figures 1 - 8, Supplementary Tables 1 - 5, Supplementary Material 1 - 6

###### 

Supplementary Figure 5

###### 

Supplementary Figure 6

We thank the MRI Animal Resource Facility staff for animal care. We thank Bruz Marzolf and Krassen Dimitrov at the microarray core facility at ISB for technical support. We also thank David Galas and Gilbert Omenn for thorough reviews. We thank Gustavo Glusman for his assistance in visualizing time series expression profiles with circular heatmaps. We are grateful to Alan Aderem, John Bermingham, Ranjit Giri, and Rajeev Kumar for helpful discussions. This study was supported by grants from the National Prion Research Program, US Department of Defense (Grants DAMD17-03-1-0321 and DAMD17-03-1-0425) and from NIH grants NS41997 and GM076547.

The authors declare that they have no conflict of interest.

![Strategies for identification of 333 core differentially expressed genes (DEGs) and their functional analysis in mouse prion diseases. Two prion strains (RML and 301V) were used for inoculating mice from six different genetic backgrounds (B6, B6.I, FVB, Tg4053, 0/+, and 0/0) to generate eight prion--mouse combinations. From the list of 7400 DEGs identified from at least one of the five combinations with normal levels of prion protein (1X), 333 DEGs shared by all five were selected through novel statistical methods to represent perturbed networks essential to prion pathophysiology. Venn diagram shows the overlap of the 333 DEGs with DEGs from Tg4053-RML (mice expressing eight times of normal prion protein levels) and from 0/+-RML (mice expressing one-half of normal prion protein levels). Among 333 DEGs, 161 genes were mapped to networks through protein--protein interaction network or metabolic pathways. Also, by comparison of 333 DEGs with previous prion microarray studies, we identified 178 DEGs that have not been reported in connection with prion disease.](msb200910-f1){#f1}

![Expression profiles of genes shared among comparison of five mouse--prion combinations or unique to Tg4053-RML. Dynamic gene expression profiles in all eight mouse strain--prion strain combinations are shown for three cases in the order of B6-RML, B6-301V, B6.I-RML, B6.I-301V, FVB-RML, Tg4053-RML, 0/+-RML, and 0/0-RML: (**A**) top 20 genes with highest statistical significance for involvement in prion pathology among 333 differentially expressed genes (DEGs) shared by five combinations, B6-RML, B6-301V, B6.I-RML, B6.I-301V, and FVB-RML; (**B**) bottom 20 genes with lowest statistical significance for involvement in prion pathology among 333 shared DEGs; and (**C**) top 20 DEGs with highest statistical significance for involvement in prion pathology among RML-infected Tg4053 mice.](msb200910-f2){#f2}

![Time course histoblots and profiles of selected DEGs in three mouse strains with varying PrP^C^ concentration. (**A**) Histoblots are shown for dynamic patterns of accumulation of proteinase K-resistant PrP^Sc^ in brains of RML-infected mice with wild-type PrP^C^ concentration (FVB), half of wild-type PrP^C^ concentration (0/+), and approximately eight times of wild-type PrP^C^ concentration (Tg4053). (**B**) Expression profiles of shared DEGs representing key network modules are shown for FVB, Tg4053, and 0/+ mice. No significant changes were detected for these genes in mice lacking the Prnp gene (0/0). Percentage of the incubation times (incubation time is defined in this paper as the time period from prion inoculation to end point) for the time points when gene expression changes start to occur are indicated with arrows in histoblot series (A) and gene expression profiles (B).](msb200910-f3){#f3}

![Dynamic PrP replication and accumulation network. Hypothetical networks of proteins and metabolites that are potentially involved in PrP replication and accumulation were constructed starting from the list of 333 shared DEGs and protein--protein interaction/metabolic pathway information from public databases. Relative changes of the transcripts for the corresponding proteins are represented in color changes: red---upregulation, green---downregulation, yellow---no change. Data for the transcriptional changes are from BL6 mice infected with RML prions, at 6 weeks (**A**), 10 weeks (**B**), 14 weeks (**C**), 18 weeks (**D**), 20 weeks (**E**), and 22 weeks (**F**) after inoculation. See main text for detailed description of modules 1 through 6. Ch: cholesterol; ECM: extracellular matrix; PM: plasma membrane. Large nodes indicate DEGs whose expression change patterns are shared by five prion--mouse combinations (B6-RML, B6-301V, B6.I-RML, B6.I-301V, and FVB-RML); asterisks indicate DEGs whose prion-related changes are unique in this study; genes in blue are also DEGs in RML-infected 0/+ mice; genes in bold are also DEGs in RML-infected Tg4053 mice; genes with solid underline were changed only in mice with short incubation times; genes with dotted underline were changed only in RML-infected mice. Source data is available for this figure at [www.nature.com/msb](http://www.nature.com/msb)](msb200910-f4){#f4}

![Microglial and astrocyte activation network. Hypothetical networks of proteins and metabolites that are potentially involved in activation of microglia and astrocytes were constructed starting from the list of 333 shared DEGs and protein--protein interaction information from public databases. Modules A--F denote distinct functional modules within the network: (A) Complement activation, (B) pattern recognition receptors, (C) cytokines and chemokines, (D) growth factors, (E) reactive astrogliosis, and (F) leukocyte extravasation. Relative changes of the transcripts for the corresponding proteins are represented in color changes: red---upregulation, green---downregulation, yellow---no change. Data for differential expression are from BL6 mice infected with RML prions. The temporal expression changes at six time points (10, 14, 16, 18, 20, and 22 weeks) are represented by the circular heatmaps of the network nodes: the center color of each node indicates the differential expression at 10 weeks, while the outer circle colors represent expression changes at increasing time points. Large nodes indicate DEGs whose expression change patterns are shared by five prion-mouse combinations; asterisks indicate DEGs whose prion-related changes are unique in this study; genes in blue are also DEGs in RML-infected 0/+ mice; genes in bold are also DEGs in RML-infected Tg4053 mice; genes with solid underline were changed only in mice with short incubation times. Source data is available for this figure at [www.nature.com/msb](http://www.nature.com/msb)](msb200910-f5){#f5}

![Novel functional modules with dynamic gene expression changes potentially linked to prion pathophysiology: (**A**) androgen metabolism, (**B**) iron metabolism, (**C**) arachidonate/phospholipid metabolism. Hypothetical networks of proteins and metabolites that are potentially involved in three novel functional modules were constructed based on genes selected from the list of 333 shared DEGs and metabolic pathway information from literature. The temporal expression changes at six time points (10, 14, 16, 18, 20, and 22 weeks after inoculating BL6 mice with RML prions) are represented by the circular heatmaps of the network nodes: the center color of each node indicates the differential expression at 10 weeks, whereas the outer circle colors represent expression changes at increasing time points. Large nodes indicate DEGs whose expression change patterns are shared by five mouse-prion combinations; asterisks indicate DEGs whose prion-related changes are unique in this study. See text for detailed description of the three pathways.](msb200910-f6){#f6}

![Expression profiles of DEGs changing predominantly in three short incubation time combinations or in two RML-infected mice. (**A**) Top 10 genes that show selective changes in short incubation time combinations, B6-RML, B6.I-301V, and FVB-RML as compared with long incubation time combinations (B6-301V and B6.I-RML). The changes of these genes in 0/+ is also shown as another example of mouse--prion combination with long incubation time; (**B**) top 10 genes that show selective changes in RML-infected combinations, B6-RML and B6.I-RML as compared with 301V-infected combinations, B6-301V and B6.I-301V.](msb200910-f7){#f7}

###### 

Mouse strain--prion strain combinations

  Mouse strain                                *Prnp* genotype   Prion strain    End point[^a^](#t1-fn1){ref-type="fn"} (days/weeks)  Harvest interval[^b^](#t1-fn2){ref-type="fn"} (weeks)
  ------------------------------------------- ----------------- -------------- ----------------------------------------------------- -------------------------------------------------------
  C57BL/6J (B6)                               *a/a*             RML                                   161/23                         2
  C57BL/6J (B6)                               *a/a*             301V                                  287/41                         4
  C57BL/6.I-1 (B6.I)                          *b/b*             RML                                   336/48                         4
  C57BL/6.I-1 (B6.I)                          *b/b*             301V                                  126/18                         2
  FVB/NCr (FVB)                               *a/a*             RML                                   154/22                         2
  FVB-Tg(PrP-A)4053 (Tg4053)                  \>*30a*           RML                                    56/8                          1
  (FVB x FVB.129-*Prnp*^*tm1Zrch*^)F1 (0/+)   *a/0*             RML                                   392/56                         4
  FVB.129*-Prnp*^*tm1Zrch*^ (0/0)             *0/0*             RML                     196/28[^c^](#t1-fn3){ref-type="fn"}          4

^a^End point is equivalent to the incubation time in this study, which is defined as the interval between prion inoculation to end point. With the exception of 0/0 mice, all animals were at the terminal stages of disease when killed for brain harvest. For each combination, a set of mice was inoculated with brain homogenate from normal mice and brains were harvested at the same time points as prion-infected mice.

^b^Brains from three mice were taken at each time point. In a few instances, the interval deviated from that shown. For example, the final interval for B6-RML was 1 week due to severity of illness in these mice. The actual intervals are indicated in figures that follow.

^c^Additional three RML-inoculated and three normal brain homogenate-inoculated 0/0 mice were aged 357 days (51 weeks).

###### 

Novel functions represented by selected genes from 333 DEGs (differentially expressed genes) shared by five mouse--prion combinations

  Category                                                             Gene symbol[^a^](#t2-fn1){ref-type="fn"}   Description                                                                    Entrez ID   Previous studies[^b^](#t2-fn2){ref-type="fn"}   Human orthologs[^c^](#t2-fn3){ref-type="fn"}
  -------------------------------------------------------------------- ------------------------------------------ ------------------------------------------------------------------------------ ----------- ----------------------------------------------- ----------------------------------------------
  Leukocyte extravasation                                              Csf1^\*^                                   Colony-stimulating factor 1 (macrophage)                                       12977                                                       CSF1
                                                                       Prg1^\*^                                   Proteoglycan 1, secretory granule                                              19073                                                       SRGN
                                                                       Selpl^\*^                                  Selectin, platelet (p-selectin) ligand                                         20345                                                       SELPLG
                                                                       Cyba                                       Cytochrome *b*-245, alpha polypeptide                                          13057       R, X4                                           CYBA
                                                                       Itgax                                      Integrin alpha X                                                               16411       R, X4                                           ITGAX
                                                                       Msn                                        Moesin                                                                         17698       R, X4                                           MSN
  Androgen metabolism                                                  Cyp7b1^\*^                                 Cytochrome *P*450, family 7, subfamily b, polypeptide 1                        13123                                                       CYP7B1
                                                                       Hsd3b7^\*^                                 Hydroxy-delta-5-steroid dehydrogenase, 3 beta- and steroid delta-isomerase 7   101502                                                      HSD3B7
                                                                       Slco2b1^\*^                                Solute carrier organic anion transporter family, member 2b1                    101488                                                      SLCO2B1
                                                                       Bzrp                                       Benzodiazepine receptor, peripheral                                            12257       X                                               TSPO
                                                                       Dbi                                        Diazepam-binding inhibitor                                                     13167       S, Sk, Bo                                       DBI
  Iron homeostasis and heme metabolism                                 Cp^\*^                                     Ceruloplasmin                                                                  12870                                                       CP
                                                                       Hfe^\*^                                    Hemochromatosis                                                                15216                                                       HFE
                                                                       Slc39a14^\*^                               Solute carrier family 39 (zinc transporter), member 14                         213053                                                      SLC39A14
                                                                       Ftl1                                       Ferritin light chain 1                                                         14325       Sk                                              FTL
                                                                       Trf                                        Transferrin                                                                    22041       Sk, Bo                                          TF
  Demyelination, neurogenesis, axonal transport, ion channels          *Kif5c\**                                  Kinesin family member 5C                                                       16574                                                       KIF5C
                                                                       Lgi4^\*^                                   Leucine-rich repeat LGI family, member 4                                       243914                                                      LGI4
                                                                       Nupr1^\*^                                  Nuclear protein 1                                                              56312                                                       NUPR1
                                                                       P2rx7^\*^                                  Purinergic receptor P2X, ligand-gated ion channel, 7                           18439                                                       P2RX7
                                                                       *Scn1a\**                                  Sodium channel, voltage-gated, type I, alpha                                   20265                                                       SCN1A
  Arachidonate/phospholipid metabolism and calcium signaling pathway   Alox5ap^\*^                                Arachidonate 5-lipoxygenase-activating protein                                 11690                                                       ALOX5AP
                                                                       Cyp4f14^\*^                                Cytochrome *P*450, family 4, subfamily f, polypeptide 14                       64385                                                       CYP4F2
                                                                       Ptgs1^\*^                                  Prostaglandin-endoperoxide synthase 1                                          19224                                                       PTGS1
                                                                       Hpgd                                       Hydroxyprostaglandin dehydrogenase 15 (NAD)                                    15446       Bo, R                                           HPGD
                                                                       Plce1^\*^                                  Phospholipase C, epsilon 1                                                     74055                                                       PLCE1
                                                                       Adcy7^\*^                                  Adenylate cyclase 7                                                            11513                                                       ADCY7
  Hematopoiesis                                                        Gmfg^\*^                                   Glia maturation factor, gamma                                                  63986                                                       GMFG
                                                                       Inpp5d                                     Inositol polyphosphate-5-phosphatase D                                         16331       X                                               INPP5D
                                                                       Lcp1                                       Lymphocyte cytosolic protein 1                                                 18826       X4                                              LCP1
                                                                       Lpxn                                       Leupaxin                                                                       107321      X                                               LPXN
                                                                       Nckap1l                                    NCK-associated protein 1 like                                                  105855      X                                               NCKAP1L
                                                                                                                                                                                                                                                              
  Old gene symbols[^d^](#t2-fn4){ref-type="fn"}                        Updated gene symbol                        Description                                                                    Entrez ID                                                    
  Bzrp                                                                 Tspo                                       Translocator protein                                                           12257                                                        
  Prg1                                                                 Srgn                                       Serglycin                                                                      19073                                                        
  Selpl                                                                Selplg                                     Selectin, platelet (p-selectin) ligand                                         20345                                                        

^a^Genes with asterisk are unique DEGs to this study; genes in bold and italic show decreased expression in infected mouse brains.

^b^S ([@b82]); X ([@b96]); Sk ([@b81]); Br ([@b11]); Bo ([@b7]); R ([@b74]); X4 ([@b97]).

^c^Orthologous human gene symbols are current as of 28 August 2008.

^d^Gene symbols have been updated in the EntrezGene database as of 28 August 2008.

###### 

Functions predicted for selected genes from 333 DEGs shared by five mouse--prion combinations

  Category                                        Gene symbol[^a^](#t3-fn1){ref-type="fn"}   Description                                                                Entrez ID   Previous studies[^b^](#t3-fn2){ref-type="fn"}   Human orthologs[^c^](#t3-fn3){ref-type="fn"}
  ----------------------------------------------- ------------------------------------------ -------------------------------------------------------------------------- ----------- ----------------------------------------------- ----------------------------------------------
  Protection against oxidative stress             Naprt1^\*^                                 Nicotinate phosphoribosyltransferase domain containing 1                   223646                                                      NAPRT1
  Arachidonate/phospholipid metabolism            Bmp2k^\*^                                  BMP2-inducible kinase                                                      140780                                                      BMP2K
                                                  E030018N11Rik^\*^                          RIKEN cDNA E030018N11 gene                                                 319622                                                      ITPRIPL2
  Hematopoiesis                                   Pbxip1^\*^                                 Pre-B-cell leukemia transcription factor interacting protein 1             229534                                                      PBXIP1
  Chondrogenesis                                  Loh11cr2a^\*^                              Loss of heterozygosity, 11, chromosomal region 2, gene A homolog (human)   67776                                                       VWA5A
  Complement system (coagulation)                 Pp11r^\*^                                  Placental protein 11 related                                               19011                                                       P11
                                                  BC032204                                   cDNA sequence BC032204                                                     108101      X, X4                                           FERMT3
  Interferon-related                              Aldh1l2^\*^                                Aldehyde dehydrogenase 1 family, member L2                                 216188                                                      ALDH1L2
                                                  D12Ertd647e^\*^                            DNA segment, Chr 12, ERATO Doi 647, expressed                              52668                                                       NA
                                                  Plscr2^\*^                                 Phospholipid scramblase 2                                                  18828                                                       PLSCR2
  Other immune response genes                     4632428N05Rik^\*^                          RIKEN cDNA 4632428N05 gene                                                 74048                                                       C10orf54
                                                  Stno^\*^                                   Strawberry notch homolog (Drosophila)                                      216161                                                      SBNO2
                                                  Gp49a                                      Glycoprotein 49 A                                                          14727       X, R                                            NA
  Metal ion binding                               Antxr1^\*^                                 Anthrax toxin receptor 1                                                   69538                                                       ANTXR1
                                                  Dtx3l^\*^                                  Deltex 3-like (*Drosophila*)                                               209200                                                      DTX3L
                                                  Eya4^\*^                                   Eyes absent 4 homolog (*Drosophila*)                                       14051                                                       EYA4
  Membrane trafficking                            Crispld2^\*^                               Cysteine-rich secretory protein LCCL domain containing 2                   78892                                                       CRISPLD2
  Signal transduction                             4933428I03Rik^\*^                          RIKEN cDNA 4933428I03 gene                                                 66775                                                       PTPLAD2
  Nucleic acid binding                            Scrg1                                      Scrapie responsive gene 1                                                  20284       DD                                              SCRG1
  DNA damage repair                               Parp12^\*^                                 Poly (ADP-ribose) polymerase family, member 12                             243771                                                      PARP12
  Guanylate binding                               Mpa2l^\*^                                  Macrophage activation 2 like                                               100702                                                      NA
  Neurological disorder related                   0610011I04Rik^\*^                          RIKEN cDNA 0610011I04 gene                                                 66058                                                       TMEM176A
                                                  1810009M01Rik^\*^                          RIKEN cDNA 1810009M01 gene                                                 65963                                                       TMEM176B
                                                  Phyhd1^\*^                                 Phytanoyl-CoA dioxygenase domain containing 1                              227696                                                      PHYHD1
  Non-coding genes                                AU020206                                   Expressed sequence AU020206                                                101757      X4                                              NA
                                                  2310033F14Rik^\*^                          RIKEN cDNA 2310033F14 gene                                                 69555                                                       NA
  No predicted functions                          1810059G22Rik^\*^                          RIKEN cDNA 1810059G22 gene                                                 67706                                                       TMEM179B
                                                  2310014H01Rik^\*^                          RIKEN cDNA 2310014H01 gene                                                 76448                                                       KIAA1949
                                                  *4933411K20Rik\**                          RIKEN cDNA 4933411K20 gene                                                 66756                                                       KIAA1430
                                                  9230105E10Rik^\*^                          RIKEN full-length enriched library, clone: A130050C20 product              245575                                                      NA
                                                  A530050D06Rik^\*^                          RIKEN cDNA A530050D06 gene                                                 104816                                                      LOC374569
                                                  AI452102^\*^                               Expressed sequence AI452102                                                330594                                                      NA
                                                  E230029C05Rik^\*^                          RIKEN cDNA E230029C05 gene                                                 319711                                                      NA
                                                  2810459M11Rik                              RIKEN cDNA 2810459M11 gene                                                 72792       X                                               C2orf72
                                                  BC025600                                   cDNA sequence BC025600                                                     231633      X, Sk                                           TMEM119
                                                  X99384                                     cDNA sequence X99384                                                       27355       X                                               KIAA1274
                                                                                                                                                                                                                                     
  Old gene symbols[^d^](#t3-fn4){ref-type="fn"}   Updated gene symbol                        Description                                                                Entrez ID   Comments                                         
  0610011I04Rik                                   Tmem176a                                   Transmembrane protein 176A                                                 66058                                                        
  1810009M01Rik                                   Tmem176b                                   Transmembrane protein 176B                                                 65963                                                        
  1810059G22Rik                                   Tmem179b                                   Transmembrane protein 179B                                                 67706                                                        
  4933428I03Rik                                   Ptplad2                                    Protein tyrosine phosphatase-like A domain containing 2                    66775                                                        
  AI452102                                        E230029C05Rik                              RIKEN cDNA E230029C05 gene                                                 330594      New GeneID: 319711                               
  BC025600                                        Tmem119                                    Transmembrane protein 119                                                  231633                                                       
  BC032204                                        Fermt3                                     Fermitin family homolog 3                                                  108101                                                       
  Cklfsf6                                         Cmtm6                                      CKLF-like MARVEL transmembrane domain containing 6                         67213                                                        
  Loh11cr2a                                       Vwa5a                                      von Willebrand factor A domain containing 5A                               67776                                                        
  Stno                                            Sbno2                                      Strawberry notch homolog 2                                                 216161                                                       

^a^Genes with asterisk are unique DEGs to this study; gene in bold and italic shows decreased expression in infected mouse brains.

^b^X ([@b96]); Sk ([@b81]); R ([@b74]); X4 ([@b97]); DD ([@b22]).

^c^Orthologous human gene symbols are current as of 28 August 2008. Those denoted as 'NA\' do not have official orthologous human genes.

^d^Gene symbols of the following 10 genes have been updated in the EntrezGene database as of 28 August 2008.

[^1]: These authors contributed equally to this work
